JUN 05, 2014 08:00 AM PDT
Exploring High Resolution Accurate Mass Orbitrap Technology for Comprehensive Urine Drug Screening
SPONSORED BY: Thermo Fisher Scientific
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: CE
124 40 5102

Speakers:
  • Discipline Chief, Clinical Biochemist/Toxicologist, Centre for Addiction and Mental Health
    Biography
      Dr. Cristiana Stefan is licentiate in fundamental Biochemistry, and holds a PhD degree in Medical Sciences which she received in 1999 from the Catholic University of Leuven, Belgium. After that she came to Canada, and pursued a career in Clinical Chemistry. She obtained a Diploma in Clinical Chemistry in 2002 at the University of Toronto, followed by a fellowship in Toxicology at Hospital for Sick Children in Toronto. Since 2009, Dr. Stefan is a Diplomate of the American Board of Clinical Chemistry and is certified in both Clinical Chemistry and Toxicological Chemistry. She is a Fellow of National Academy of Clinical Biochemistry, an academy of the American Association of Clinical Chemistry. Currently, she is the Clinical Biochemist and Toxicologist at the Clinical Laboratory and Diagnostic Services at CAMH (Centre for Addiction and Mental Health). The laboratory is using state of the art technology for drugs of abuse testing, earning a reputation of centre of excellence, and has extensive expertise in testing for tetrahydrocannabinol and metabolites in various body fluids.

    Abstract:

     

    This webinar presents the experience gained at our laboratory with comprehensive urine drug screening for clinical research using the Thermo Scientific™ Q Exactive™ hybrid quadrupole-Orbitrap high resolution mass spectrometer and Thermo Scientific™ Accela™ UPLC.

    Our journey started with establishing a database with monoisotopic masses for the drugs we were interested in, including a variety of metabolite, as well as a very simple dilute-and-shoot protocol, using full data scan/ddMS2 and fast LC gradient. We then used available drug standards to build an extensive library comprising of mass fragmentation spectra and retention times of 1200 compounds. For metabolites that had no standards available, accurate mass was used to extract the mass peak from the chromatograms of known users and corresponding MS2 spectra were collected.

    Using the Q Exactive Orbitrap mass spectrometer, we are able to answer relevant questions for urine drug screening. Is this drug absent or present in the urine? Are both parent and metabolites present, or only the metabolite(s)? Which metabolites? Does the metabolite pattern relate to recent or past use? Using this technology we were also able to identify current designer drugs of abuse such synthetic cannabinoids and bath salts.

    For forensic toxicology use only.


    Show Resources
    Loading Comments...